

Clinical trials of voglibose

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
mitiglinide+voglibose vs insulin glargine			
GLORIA [NCT00663884] n=NA follow-up: 16 weeks	combination therapy of 10 mg mitiglinide or 0.2mg voglibose versus insulin glargine	diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine	open Korea
voglibose vs placebo			
Voglibose Ph-3 , 2009 [UMIN 000001109-] n=897/881 follow-up: 4.01 years	voglibose 0.2 mg three times daily versus placebo	patients with impaired fasting glucose	Parallel groups double blind Japan

┌ More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q341>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- prevention for diabetes type 2 in people with impaired glucose tolerance at <http://www.trialresultscenter.org/go-Q416>
- insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q549>

References

GLORIA, 0:

Voglibose Ph-3, 2009:

Scheen AJ Voglibose for prevention of type 2 diabetes mellitus. Lancet 2009;373:1579-80 [19395080]

Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14 [19395079]

2 impaired fasting glucose

Trial	Treatments	Patients	Trials design and methods
voglibose vs placebo			
Voglibose Ph-3 , 2009 [UMIN 000001109-] n=897/881 follow-up: 4.01 years	voglibose 0.2 mg three times daily versus placebo	patients with impaired fasting glucose	Parallel groups double blind Japan

More details and results :

- prevention for impaired fasting glucose in all type of patients at <http://www.trialresultscenter.org/go-Q342>

References

Voglibose Ph-3, 2009:

Scheen AJ Voglibose for prevention of type 2 diabetes mellitus. Lancet 2009;373:1579-80 [19395080]

Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14 [19395079]

Entry terms: voglibose, Basen,